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1  |  INTRODUC TION
Ambulatory blood pressure monitoring (ABPM)— the measurement 
of blood pressure (BP) over a 24- h period— is the reference standard 
for BP measurement.1 ABPM results predict cardiovascular disease 
(CVD) events and mortality more accurately than clinic BP measure-
ments.2 Additionally, ABPM allows for the identification of high- risk 
phenotypes— including nocturnal non- dipping of BP and heart rate 
(HR)— which cannot be diagnosed in the clinic.
People with HIV (PWH) have a twofold to fourfold higher inci-
dence of CVD.3,4 This increased risk may be partly attributable to ab-
normalities in nocturnal BP and HR.5 We do not yet know whether 
these ABPM abnormalities observed in PWH differ by clinic BP status.
Therefore, we conducted a nested case- control study com-
paring ABPM in PWH with normal and high clinic BP and HIV- 
uninfected controls in Tanzania. Objectives of this research were 
as follows: 1) to compare nocturnal non- dipping of BP and HR 
between PWH and HIV- uninfected controls and 2) to determine 
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Abstract
People with HIV (PWH) have a >2- fold greater risk for development of cardiovascular 
disease (CVD), which may be associated with abnormalities in 24- h ambulatory blood 
pressure measurement (ABPM) profile. We conducted a nested case- control study 
of ABPM in 137 PWH and HIV- uninfected controls with normal and high clinic blood 
pressure (BP) in Tanzania. Nocturnal non- dipping of heart rate (HR) was significantly 
more common among PWH than HIV- uninfected controls (p = .01). Nocturnal non- 
dipping of BP was significantly more common in PWH with normal clinic BP (p = .048). 
Clinical correlates of nocturnal non- dipping were similar in PWH and HIV- uninfected 
adults and included higher BMI, higher CD4+ cell count, and high C- reactive protein 
for HR and markers of renal disease for BP. In conclusion, nocturnal non- dipping of 
both BP and HR was more common in PWH but further research is needed to deter-
mine causes and consequences of this difference.
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correlates of nocturnal non- dipping of BP and HR in PWH and 
HIV- uninfected controls.
2  |  METHODS
2.1  |  Study cohort
This nested case- control study was conducted within a well- 
described prospective cohort6 of PWH attending an outpatient HIV 
clinic in Tanzania and HIV- uninfected controls.
2.2  |  Study population
Cohort inclusion criteria include age 18- 65 years, Tanzanian citizen-
ship, and residing in Mwanza City. Exclusion criteria for both groups 
include previous history of CVD and a medical condition with a prog-
nosis of <12 months.
2.3  |  Study location
All study activities were performed in the outpatient HIV clinic at 
Bugando Medical Centre, in Mwanza, Tanzania.
2.4  |  Study procedures
Study procedures have been described in detail previously.6 At each 
study visit, a standardized questionnaire and physical examination 
were administered. Automated BP was measured using an OMRON 
HBP- 1300 (OMRON Healthcare) professional BP monitor. High 
clinic BP was defined as BP measurements (≥140/90 mmHg) on at 
least two consecutive visits according to the International Society of 
Hypertension (ISH) threshold.7
2.5  |  Ambulatory blood pressure monitoring 
study design
From February 2018 to June 2018, we performed ABPM on 50 con-
secutive cohort participants attending scheduled research clinic ap-
pointments with normal clinic BP. We also performed ABPM on all 
participants with high clinic BP.
2.6  |  Ambulatory blood pressure measurement
Ambulatory blood pressure monitoring was performed using the 
validated SunTech Medical® Oscar 2 machine, programmed via the 
AccuWin Pro 4 software to measure BP for 24 h at an interval 
of 15 min. Initial readings were confirmed in- clinic. Participants 
were instructed to return to the clinic after 24 h. The following 
day self- reported sleep and wake times were recorded. All partici-
pants identified as hypertensive were referred to a physician and 
offered free hypertension treatment according to the Tanzanian 
guidelines.8,9 All ABPM met European Society of Hypertension 
(ESH) quality control guidelines for ABPM, which require >20 day-
time and >7 nighttime measurements, and ≥70% valid measure-
ments of expected measurements. Nocturnal non- dipping of HR/
BP was defined as an asleep HR/BP reduction of ≥10% of awake 
values.10
2.7  |  Laboratory procedures
CD4+ T- cell count was measured using an automated BD FACS 
Calibur Machine (BD Biosciences) for PWH. Serum creatinine level 
was measured using the A25 Analyzer (Biosystems), calibrated 
by the creatinine Jaffé 2 method. An estimated glomerular filtra-
tion rate (eGFR) was calculated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD- EPI) Equation.11 Urine albumin 
and creatinine were measured with the Siemens DCA Vantage 
Analyzer (Siemens Healthcare). High- sensitivity serum C- reactive 
protein (hsCRP) concentration was measured using R&D Systems 
Quantikine ELISA (R&D Systems). hsCRP measurements were clas-
sified according to cardiovascular risk,12 with hsCRP >3 mg/L repre-
senting high risk and hrCRP ≤3 mg/L representing low/intermediate 
risk.
2.8  |  Statistical methods
Data were double entered into OpenClinica (OpenClinica LLC). 
Baseline participant characteristics were summarized using me-
dian and interquartile range for continuous variables and fre-
quency and percent for categorical variables. For categorical 
variables, chi- squared tests or Fisher's exact tests, as appropriate, 
were performed to evaluate the association between HIV status 
and BP/HR dipping status. Multivariate logistic regression analy-
ses adjusted for clinic systolic blood pressure (SBP) were used to 
evaluate factors associated with nocturnal non- dipping of BP/HR. 
All analysis was conducted using Stata version 15.1 (STATACorp 
LLC).
2.9  |  Ethics
The study was carried out in accordance with Good Clinical 
Practice and the Declaration of Helsinki. The study and con-
sent forms were approved by the Weill Cornell Medicine 
(1506016328), the Tanzanian National Institute of Medical 
Research (NIMR/HQ/R.8c/Vol.1/1399), and Bugando Medical 
Centre (CREC/074/2015). All participants provided written in-
formed consent.
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3  |  RESULTS
3.1  |  Study population and characteristics
The baseline characteristics of all study participants are displayed 
in Table S1. Of the 137 participants selected, 50 had normal clinic 
BP (25 PWH and 25 HIV- uninfected) and 87 had high clinic BP (31 
PWH and 56 HIV- uninfected). None of the participants had started 
anti- hypertensive medication at the time of ABPM measurement. All 
of the PWH were on ART. Mean duration of ART use was 1.46 years 
and ranged from 0 to 3.15 years. PWH and HIV- uninfected controls 
were similar in age, sex distribution, and BMI (Table S1). Analysis of 
the associations between HIV infection and ABPM results are in 
Table S2.
3.2  |  Nocturnal non- dipping of BP/HR in all 
participants
Overall, PWH had a higher prevalence of nocturnal non- dipping of 
HR (39.3% [22/56] in PWH vs. 19.8% [16/81] in HIV- uninfected con-
trols, p = .01) than HIV- uninfected controls. Nocturnal non- dipping 
of BP was more common in PWH but this did not reach statisti-
cal significance (64.2% [36/56] in PWH vs. 53.1% [43/81] in HIV- 
uninfected controls, p = .19).
3.3  |  Nocturnal non- dipping of BP/HR in 
participants with normal versus high clinic BP
Prevalence of nocturnal non- dipping of HR/BP stratified by HIV 
status and clinic BP is displayed in Figure 1 and Table S3. Among 
participants with normal clinic BP, PWH had a higher prevalence of 
nocturnal non- dipping of BP (64.0% [16/25] in PWH vs. 36.0% (9/25) 
in HIV- uninfected controls, p = .048). Among participants with high 
clinic BP, PWH had a higher prevalence of nocturnal non- dipping 
of HR (41.9% [13/31] in PWH vs. 21.4% [12/56] in HIV- uninfected 
controls, p = .043) than HIV- uninfected controls.
3.4  |  Correlates of non- dipping
Factors associated with nocturnal non- dipping of HR and BP in-
dependent of clinic SBP were similar in PWH and HIV- uninfected 
F I G U R E  1  Nocturnal non- dipping 
of heart rate (HR) and blood pressure 
(BP) among people with HIV (PWH) and 
HIV- uninfected control participants 
stratified by clinic BP. Panel A: Prevalence 
of nocturnal non- dipping of HR by HIV 
status. Panel B: Prevalence of nocturnal 
non- dipping of BP by HIV status
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adults and are displayed in Table 1. Nocturnal non- dipping of HR 
was associated with higher BMI (aOR 1.10, 95% CI 1.02- 1.18, 
p = .012), elevated hsCRP (aOR 2.32, 95% CI 1.05- 5.11, p = .036), 
and CD4+ T- cell count per 100 cells/mm3 among PWH (aOR 1.19, 
95% 1.00- 1.42, p = 048). Nocturnal non- dipping of BP was as-
sociated with eGFR <60 ml/min/1.73m2 (aOR 4.48, 95% CI 1.18- 
16.99, p = .027) and ACR ≥30 mg/g (aOR 3.96, 95% CI 1.05- 14.86, 
p = .042).
4  |  DISCUSSION
In this study of ABPM in Tanzania, we report that PWH have a higher 
prevalence of nocturnal non- dipping of both HR and BP than HIV- 
uninfected participants. Overall, PWH were twice as likely (40% vs. 
20%) to have nocturnal non- dipping of HR. In addition, PWH with 
normal clinic BP were twice as likely to have nocturnal non- dipping 
of BP (64% vs. 36%). Correlates of nocturnal non- dipping were simi-
lar in PWH and HIV- uninfected adults: HR non- dipping was associ-
ated with higher BMI, higher CD4+ cell count, and high hsCRP, and 
BP non- dipping was associated with both albuminuria and reduced 
eGFR.
Nocturnal non- dipping of HR was twice as common in PWH as 
in HIV- uninfected controls, regardless of BP status (40% vs. 20%). 
To the best of our knowledge, we are the first to report this higher 
rate of nocturnal non- dipping of HR in PWH. Emerging data indicate 
that nocturnal non- dipping of HR may independently predict CVD 
events and mortality in the general population.13 Nocturnal non- 
dipping of HR was independently associated with higher hsCRP, in-
dicating that non- dipping of HR in PWH could be related to chronic 
vascular inflammation. Nocturnal non- dipping of HR might partly 
explain the known association between elevated CRP and CVD and 
could provide a target for intervention.
Two- thirds of PWH and half of HIV- uninfected participants 
exhibited nocturnal non- dipping of BP. This difference was par-
ticularly pronounced among participants with normal clinic BP, 
where two- thirds of PWH and just one- third of HIV- uninfected 
controls had nocturnal non- dipping of BP. In the general pop-
ulation, this “normotensive non- dipper” phenotype has been 
associated with higher rates of CVD events independent of day-
time BP, but this phenotype not been studied in PWH.14 Previous 
studies of nocturnal non- dipping of BP in PWH have consistently 
shown higher rates of nocturnal non- dipping of BP compared with 
HIV- uninfected adults, but have not investigated whether this 
difference varied by clinic BP status.5 Normotensive nocturnal 
non- dipping of BP deserves further investigation as possible new 
targets for CVD prevention in PWH.
Our study has limitations, including the small sample size and 
cross- sectional study design. In addition, HIV viral load was not 
performed at our clinic at the time of the study due to a national 
stockout of reagent. Lastly, due to the manual labor required daily 
in Tanzania, many participants had 1– 2 h per day when they did not 
meet the final ESH quality control criteria of ≥2 valid measurements 
per daytime hour and ≥1 valid measurement per nighttime hour. 
However, studies indicate that ABPM with as few as eight daytime 
readings and four nighttime readings likely still retain diagnostic and 
predictive accuracy.15
In conclusion, PWH had a higher prevalence of nocturnal non- 
dipping of BP and HR. Future research should determine the causes 
and consequences of nocturnal non- dipping of BP and HR in PWH 
to determine if non- dipping could be a novel target for intervention 
to prevent CVD in PWH.
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